Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry
- PMID: 21393391
- PMCID: PMC3198486
- DOI: 10.1378/chest.10-1166
Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry
Abstract
Background: Pulmonary arterial hypertension (PAH) is a progressive and fatal disorder. Despite the emergence of effective therapy, PAH is commonly at an advanced stage when recognized. Factors associated with a prolonged symptomatic period before the recognition of PAH have not been fully evaluated.
Methods: The Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL Registry) enrolled 2,967 US adult patients with PAH from March 2006 to September 2007. Patients were considered to have delayed disease recognition if > 2 years elapsed between symptom onset and the patient receiving a PAH diagnosis, starting on PAH-specific therapy, or receiving a diagnosis by right-sided heart catheterization.
Results: In 21.1% of patients, symptoms were experienced for > 2 years before PAH was recognized. Patients with onset of PAH symptoms before age 36 years showed the highest likelihood of delayed disease recognition (OR, 3.07; 95% CI, 2.03-4.66). History of obstructive airways disease (OR, 1.93; 95% CI, 1.5-2.47) and sleep apnea (OR, 1.72; 95% CI, 1.33-2.22) were independently associated with delayed PAH recognition. Six-minute walk distance < 250 m (OR, 1.91; 95% CI, 1.16-3.13), right atrial pressure < 10 mm Hg (OR, 1.77; 95% CI, 1.26-2.48), and pulmonary vascular resistance < 10 Wood units (OR, 1.28; 95% CI, 1.02-1.60) were also associated with delayed disease recognition, but sex, race/ethnicity, and geographic region showed no association.
Conclusions: One in five patients in the REVEAL Registry who were diagnosed with PAH reported symptoms for > 2 years before their disease was recognized. Younger individuals and patients with histories of common respiratory disorders were most likely to experience delayed PAH recognition.
Trial registry: ClinicalTrials.gov; No.: NCT00370214; URL: www.clinicaltrials.gov.
Figures
Comment in
-
The early diagnosis of pulmonary arterial hypertension: can we do better?Chest. 2011 Jul;140(1):4-6. doi: 10.1378/chest.11-1149. Chest. 2011. PMID: 21729886 No abstract available.
References
-
- Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54(suppl 1):S43–S54. - PubMed
-
- McGoon MD, Torbicki A, Oudiz RJ. Diagnosis and Assessment of Pulmonary Arterial Hypertension. West Sussex, England: John Wiley and Sons, Ltd; 2008.
-
- Voelkel NF, Quaife RA, Leinwand LA, et al. National Heart, Lung, and Blood Institute Working Group on Cellular and Molecular Mechanisms of Right Heart Failure Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation. 2006;114(17):1883–1891. - PubMed
-
- Tueller C, Stricker H, Soccal P, et al. Swiss Society for Pulmonary Hypertension Epidemiology of pulmonary hypertension: new data from the Swiss registry. Swiss Med Wkly. 2008;138(25-26):379–384. - PubMed
-
- Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173(9):1023–1030. - PubMed